Determining Direct, Indirect Healthcare and Social Costs for Diabetic Retinopathy Management: a Systematic Review

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2024 Sep 30

PMID 39350064

Authors

Mawdda Benhamza

Maznah Dahlui

Mas Ayu Said

Affiliations

Soon will be listed here.

Abstract

Introduction: Diabetic retinopathy (DR) is a rapidly growing global public health threat; it affects 1 in 3 people with diabetes and is still the leading cause of blindness among the working-age population. The management of diabetic retinopathy is becoming more advanced and effective but is highly expensive compared to other ocular diseases.

Aim: To report direct medical, indirect medical, and nonmedical costs of diabetic retinopathy in developed and developing countries through a systematic review.

Methods: Related articles published in the PubMed, Google Scholar, and EMBASE electronic databases from 1985 to 2022 were identified using the keywords direct medical and indirect medical and social costs of diabetic retinopathy. However, previous systematic reviews, abstracts, and case reports were excluded.

Results: Thirteen articles were eligible for assessing the economic burden of diabetes management and its complications. Our analysis revealed that increasing prevalence and severity of diabetic retinopathy (DR) are associated with higher direct and indirect healthcare expenditures. The impact of DR on working-age adults, leading to irreversible blindness in advanced stages, underscores the urgent need for cost-effective prevention and management strategies.

Discussion: This study systematically reviewed the direct medical, indirect medical, and nonmedical costs of DR in developed and developing countries. Our findings highlight the significant economic burden of DR, emphasizing the importance of implementing effective prevention and management measures to alleviate costs and enhance patient outcomes.

Conclusion: The substantial financial burden of DR necessitates a re-evaluation of current screening and management programs. Revision of these programs is crucial to improve quality of care, reduce costs, and ultimately achieve Sustainable Development Goal 3, which aims to ensure good health and well-being for all.

Citing Articles

Use of artificial intelligence with retinal imaging in screening for diabetes-associated complications: systematic review.

Yang Q, Bee Y, Lim C, Sabanayagam C, Yim-Lui Cheung C, Wong T EClinicalMedicine. 2025; 81:103089.

PMID: 40052065 PMC: 11883405. DOI: 10.1016/j.eclinm.2025.103089.

Correlation Between the Ratio of Uric Acid to High-Density Lipoprotein Cholesterol (UHR) and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus:A Cross-Sectional Study.

Wang L, Liu L, Luo H, Wu Y, Zhu L Diabetes Metab Syndr Obes. 2025; 18:173-183.

PMID: 39866522 PMC: 11760268. DOI: 10.2147/DMSO.S504308.

References

Morsanutto A, Berto P, Lopatriello S, Gelisio R, Voinovich D, Cippo P . Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. J Diabetes Complications. 2006; 20(3):163-9. DOI: 10.1016/j.jdiacomp.2005.06.011. View

Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J . The economic burden of diabetic retinopathy in Germany in 2002. Graefes Arch Clin Exp Ophthalmol. 2007; 246(1):151-9. DOI: 10.1007/s00417-007-0573-x. View

Phillips M, del Rio I, Quiroz H . Opportunities for cost reduction in diabetic retinopathy treatment: case study from Mexico. Bull Pan Am Health Organ. 1994; 28(1):50-61. View

Orji A, Rani P, Narayanan R, Sahoo N, Das T . The economic burden of diabetic retinopathy care at a tertiary eye care center in South India. Indian J Ophthalmol. 2021; 69(3):666-670. PMC: 7942062. DOI: 10.4103/ijo.IJO_1538_20. View

Rein D, Zhang P, Wirth K, Lee P, Hoerger T, McCall N . The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006; 124(12):1754-60. DOI: 10.1001/archopht.124.12.1754. View

Lee L, Yu A, Cahill K, Oglesby A, Tang J, Qiu Y . Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin. 2008; 24(5):1549-59. DOI: 10.1185/030079908x297303. View

Heintz E, Wirehn A, Peebo B, Rosenqvist U, Levin L . Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010; 53(10):2147-54. DOI: 10.1007/s00125-010-1836-3. View

Toth G, Limburg H, Szabo D, Sandor G, Nagy Z, Nemeth J . Rapid assessment of avoidable blindness-based healthcare costs of diabetic retinopathy in Hungary and its projection for the year 2045. Br J Ophthalmol. 2020; 105(8):1116-1120. DOI: 10.1136/bjophthalmol-2020-316337. View

Parker E, Lin J, Mahoney T, Ume N, Yang G, Gabbay R . Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2023; 47(1):26-43. DOI: 10.2337/dci23-0085. View

10.

Harris S, Gittelsohn J, Hanley A, Barnie A, Wolever T, Gao J . The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 1997; 20(2):185-7. DOI: 10.2337/diacare.20.2.185. View

11.

Nagda D, Mitchell W, Zebardast N . The functional burden of diabetic retinopathy in the United States. Graefes Arch Clin Exp Ophthalmol. 2021; 259(10):2977-2986. DOI: 10.1007/s00417-021-05210-3. View

12.

OBrien J, Patrick A, Caro J . Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003; 3(1):7. PMC: 153533. DOI: 10.1186/1472-6963-3-7. View

13.

Al-Dwairi R, Aleshawi A, Abu-Zreig L, Al-Shorman W, Al Beiruti S, Alshami A . The Economic Burden of Diabetic Retinopathy in Jordan: Cost Analysis and Associated Factors. Clinicoecon Outcomes Res. 2024; 16:161-171. PMC: 10950089. DOI: 10.2147/CEOR.S454185. View

14.

Schmier J, Covert D, Lau E, Matthews G . Medicare expenditures associated with diabetes and diabetic retinopathy. Retina. 2008; 29(2):199-206. DOI: 10.1097/IAE.0b013e3181884f2d. View

15.

Kim D, Do L, Synnott P, Lavelle T, Prosser L, Wong J . Developing Criteria for Health Economic Quality Evaluation Tool. Value Health. 2023; 26(8):1225-1234. DOI: 10.1016/j.jval.2023.04.004. View

16.

Das T, Wallang B, Semwal P, Basu S, Padhi T, Ali M . Changing Clinical Presentation, Current Knowledge-Attitude-Practice, and Current Vision Related Quality of Life in Self-Reported Type 2 Diabetes Patients with Retinopathy in Eastern India: The LVPEI Eye and Diabetes Study. J Ophthalmol. 2016; 2016:3423814. PMC: 5098084. DOI: 10.1155/2016/3423814. View

17.

. Standards of medical care in diabetes--2010. Diabetes Care. 2010; 33 Suppl 1:S11-61. PMC: 2797382. DOI: 10.2337/dc10-S011. View

18.

Schmitt-Koopmann I, Schwenkglenks M, Spinas G, Szucs T . Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health. 2004; 14(1):3-9. DOI: 10.1093/eurpub/14.1.3. View

19.

Sasongko M, Wardhana F, Febryanto G, Agni A, Supanji S, Indrayanti S . The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025. Br J Ophthalmol. 2019; 104(4):487-492. DOI: 10.1136/bjophthalmol-2019-313997. View

20.

Wong T, Sabanayagam C . Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica. 2019; 243(1):9-20. DOI: 10.1159/000502387. View